MPC-150-IM
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
MPC-150-IM (rexlemestrocel-L; Mesoblast) consists of highly purified, immunoselected mesenchymal precursor cells (MPCs). These cells release a range of molecules that stimulate both blood vessel growth and regeneration of heart muscle, while also reducing scar formation and harmful inflammatory responses within the damaged tissues. These rare cells are isolated from tissues around the donor’s blood vessels and then expanded in large numbers before being administered to patients.
TABLE OF CONTENTS
4 Product Profiles
4 MPC-150-IM : Chronic heart failure (CHF)
LIST OF FIGURES
7 Figure 21: Datamonitor Healthcare’s drug assessment summary of Farxiga for chronic heart failure
9 Figure 22: Farxiga sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: MPC-150-IM drug profile
6 Table 2: MPC-150-IM’s late-phase trials in chronic heart failure
12 Table 3: MPC-150-IM sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
C-Cure 
Sign up to the